Anisomelic acid |
カタログ番号GC78810
One-Click Copy Product Info
|
Anisomelic acid is a human papillomavirus HPV16 E6 and HPV E7 depletor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 59632-76-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, Anisomelic acid (2-20 mg/kg; topical administration; once daily for 5 consecutive days) inhibits cervical cancer tumor growth in a dose-dependent manner in the chick chorioallantoic membrane (CAM) model[3].
In Vitro, Anisomelic acid (40 μM; 24 h) induces proteasome-dependent degradation of exogenous HPV16 E6 in transfected SiHa cells by enhancing E6 ubiquitination[1]. Anisomelic acid (20-40 μM; 12-24 h) downregulates the HPV16-E6 and HPV16-E7 oncoproteins and stabilizes p53 and p21 in SiHa cervical cancer cells[3]. Anisomelic acid (20-40 μM; 12-24 h) mainly induces apoptosis in SiHa cervical cancer cells by activating caspase-9, accompanied by subsequent cleavage of caspase-3 and PARP, as well as delayed cleavage of caspase-8[3]. Anisomelic acid (40 μM; 12 h) downregulates the expression of E6 and cIAP2 in SiHa cervical cancer cells, and this process is mediated by the proteasomal degradation pathway[3]. Anisomelic acid (10-40 μM; 24 h) induces concentration-dependent cell death and apoptosis in NOK16 cells by downregulating HPV16 E6[1]. Anisomelic acid (20 µM; 24 h) induces apoptosis in human cervical cancer SiHa cells; among the formulations tested, anisomelic acid loaded onto folate-chitosan coated rod-like mesoporous silica nanoparticles induces the highest level of apoptosis, which is approximately 3.2 times that of free anisomelic acid[2]. Anisomelic acid (20 µM; 24 h) activates the apoptotic machinery in SiHa human cervical cancer cells via cleavage of procaspase-3 and PARP[2]. Anisomelic acid (20-40 μM; 48 h) induces dose-dependent apoptotic DNA fragmentation in SiHa cervical cancer cells[3]. Anisomelic acid (20-40 μM; 24 h) downregulates the expression level of cIAP2 protein in SiHa cervical cancer cells[3]. Anisomelic acid (40 μM; 48 h) preferentially induces apoptosis in HPV-positive cervical cancer cells (SiHa, CaSki, HeLa) compared with HPV-negative cervical cancer cells (c33a), breast cancer cells (MCF7, MDA-MB-231), and non-cancerous MEF cells[3]. Anisomelic acid (20-40 μM; 8-48 h) induces time- and dose-dependent mitochondrial membrane depolarization in SiHa cervical cancer cells[3]. Anisomelic acid (20-40 μM; 24 h) induces G2/M phase cell cycle arrest in synchronized SiHa cervical cancer cells[3].
References:
[1]. Santos Silva M, et al. Anisomelic acid promotes proteasomal degradation of HPV16 E6 via E3 ligase recruitment: A mass spectrometry-based interactome study. Journal of proteomics. 2026 Jan 06;322:105536.
[2]. Senthilkumar R, et al. Targeted delivery of a novel anticancer compound anisomelic acid using chitosan-coated porous silica nanorods for enhancing the apoptotic effect. Biomaterials science. 2015 Jan;3(1):103-11.
[3]. Paul P, et al. Novel action modality of the diterpenoid anisomelic acid causes depletion of E6 and E7 viral oncoproteins in HPV-transformed cervical carcinoma cells. Biochemical pharmacology. 2014 May 15;89(2):171-84.
| Cas No. | 59632-76-7 | SDF | |
| Formula | C20H26O4 | M.Wt | 330.42 |
| 溶解度 | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0265 mL | 15.1323 mL | 30.2645 mL |
| 5 mM | 605.3 μL | 3.0265 mL | 6.0529 mL |
| 10 mM | 302.6 μL | 1.5132 mL | 3.0265 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)